EPO and cancer: A meta-analysis based on 14 randomised controlled trials including 2,347 cancer patients, with haematologic response to treatment with erythropoietin defined as an increase in Hb of at least 2 g/dL unrelated to transfusion, reported response rates of 9–70% [9].